全文获取类型
收费全文 | 225篇 |
免费 | 18篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 13篇 |
儿科学 | 1篇 |
妇产科学 | 1篇 |
基础医学 | 20篇 |
口腔科学 | 13篇 |
临床医学 | 11篇 |
内科学 | 44篇 |
皮肤病学 | 1篇 |
神经病学 | 25篇 |
特种医学 | 11篇 |
外科学 | 38篇 |
综合类 | 1篇 |
预防医学 | 12篇 |
眼科学 | 3篇 |
药学 | 19篇 |
中国医学 | 2篇 |
肿瘤学 | 29篇 |
出版年
2022年 | 2篇 |
2021年 | 7篇 |
2020年 | 3篇 |
2019年 | 8篇 |
2018年 | 5篇 |
2017年 | 4篇 |
2016年 | 12篇 |
2015年 | 9篇 |
2014年 | 13篇 |
2013年 | 12篇 |
2012年 | 20篇 |
2011年 | 21篇 |
2010年 | 10篇 |
2009年 | 13篇 |
2008年 | 15篇 |
2007年 | 13篇 |
2006年 | 11篇 |
2005年 | 8篇 |
2004年 | 8篇 |
2003年 | 10篇 |
2002年 | 9篇 |
2001年 | 6篇 |
2000年 | 6篇 |
1999年 | 3篇 |
1998年 | 3篇 |
1997年 | 2篇 |
1996年 | 3篇 |
1993年 | 2篇 |
1992年 | 1篇 |
1991年 | 1篇 |
1988年 | 1篇 |
1977年 | 1篇 |
1971年 | 2篇 |
排序方式: 共有244条查询结果,搜索用时 15 毫秒
241.
Benjamin Weixler Eleonora Cremonesi Roberto Sorge Manuele Giuseppe Muraro Tarik Delko Christian A. Nebiker Silvio D?ster Valeria Governa Francesca Amicarella Savas D. Soysal Christoph Kettelhack Urs W. von Holzen Serenella Eppenberger-Castori Giulio C. Spagnoli Daniel Oertli Giandomenica Iezzi Luigi Terracciano Luigi Tornillo Giuseppe Sconocchia Raoul A. Droeser 《Oncotarget》2015,6(35):37588-37599
Background
OX40 is a TNF receptor family member expressed by activated T cells. Its triggering by OX40 ligand promotes lymphocyte survival and memory generation. Anti-OX40 agonistic monoclonal antibodies (mAb) are currently being tested in cancer immunotherapy. We explored the prognostic significance of tumor infiltration by OX40+ cells in a large colorectal cancer (CRC) collective.Methods
OX40 gene expression was analyzed in 50 freshly excised CRC and corresponding healthy mucosa by qRT-PCR. A tissue microarray including 657 clinically annotated CRC specimens was stained with anti-OX40, -CD8 and -FOXP3 mAbs by standard immunohistochemistry. The CRC cohort was randomly split into training and validation sets. Correlations between CRC infiltration by OX40+ cells alone, or in combination with CD8+ or FOXP3+ cells, and clinical-pathological data and overall survival were comparatively evaluated.Results
OX40 gene expression in CRC significantly correlated with FOXP3 and CD8 gene expression. High CRC infiltration by OX40+ cells was significantly associated with favorable prognosis in training and validation sets in univariate, but not multivariate, Cox regression analysis. CRC with OX40high/CD8high infiltration were characterized by significantly prolonged overall survival, as compared to tumors with OX40low/CD8high, OX40high/CD8low or OX40low/CD8low infiltration in both uni- and multivariate analysis. In contrast, prognostic significance of OX40+ and FOXP3+ cell infiltration was not enhanced by a combined evaluation. Irrespective of TNM stage, CRC with OX40high/CD8high density infiltrates showed an overall survival similar to that of all stage I CRC included in the study.Conclusions
OX40high/CD8high density tumor infiltration represents an independent, favorable, prognostic marker in CRC with an overall survival similar to stage I cancers. 相似文献242.
243.
244.
Savarino E de Bortoli N Zentilin P Martinucci I Bruzzone L Furnari M Marchi S Savarino V 《World journal of gastroenterology : WJG》2012,18(32):4371-4378
AIM: To evaluate the effect of a novel alginate-based compound, Faringel, in modifying reflux characteristics and controlling symptoms.METHODS: In this prospective, open-label study, 40 patients reporting heartburn and regurgitation with proven reflux disease (i.e., positive impedance-pH test/evidence of erosive esophagitis at upper endoscopy) underwent 2 h impedance-pH testing after eating a refluxogenic meal. They were studied for 1 h under basal conditions and 1 h after taking 10 mL Faringel. In both sessions, measurements were obtained in right lateral and supine decubitus positions. Patients also completed a validated questionnaire consisting of a 2-item 5-point (0-4) Likert scale and a 10-cm visual analogue scale (VAS) in order to evaluate the efficacy of Faringel in symptom relief. Tolerability of the treatment was assessed using a 6-point Likert scale ranging from very good (1) to very poor (6).RESULTS: Faringel decreased significantly (P < 0.001), in both the right lateral and supine decubitus positions, esophageal acid exposure time [median 10 (25th-75th percentil 6-16) vs 5.8 (4-10) and 16 (11-19) vs 7.5 (5-11), respectively] and acid refluxes [5 (3-8) vs 1 (1-1) and 6 (4-8) vs 2 (1-2), respectively], but increased significantly (P < 0.01) the number of nonacid reflux events compared with baseline [2 (1-3) vs 3 (2-5) and 3 (2-4) vs 6 (3-8), respectively]. Percentage of proximal migration decreased in both decubitus positions (60% vs 32% and 64% vs 35%, respectively; P < 0.001). Faringel was significantly effective in controlling heartburn, based on both the Likert scale [3.1 (range 1-4) vs 0.9 (0-2); P < 0.001] and VAS score [7.1 (3-9.8) vs 2 (0.1-4.8); P < 0.001], but it had less success against regurgitation, based on both the Likert scale [2.6 (1-4) vs 2.2 (1-4); P = not significant (NS)] and VAS score [5.6 (2-9.6) vs 3.9 (1-8.8); P = NS]. Overall, the tolerability of Faringel was very good 5 (2-6), with only two patients reporting modest adverse events (i.e., nausea and bloating).CONCLUSION: Our findings demonstrate that Faringel is well-tolerated and effective in reducing heartburn by modifying esophageal acid exposure time, number of acid refluxes and their proximal migration. 相似文献